Next Article in Journal
Evaluation of Aminopolycarboxylate Chelators for Whole-Body Clearance of Free 225Ac: A Feasibility Study to Reduce Unexpected Radiation Exposure during Targeted Alpha Therapy
Next Article in Special Issue
Sorafenib Repurposing for Ophthalmic Delivery by Lipid Nanoparticles: A Preliminary Study
Previous Article in Journal
A QbD Approach for Evaluating the Effect of Selective Laser Sintering Parameters on Printability and Properties of Solid Oral Forms
Previous Article in Special Issue
Iron Oxide Nanoparticles Carrying 5-Fluorouracil in Combination with Magnetic Hyperthermia Induce Thrombogenic Collagen Fibers, Cellular Stress, and Immune Responses in Heterotopic Human Colon Cancer in Mice
Review

Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives

1
Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
2
Institute of Industrial Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Carlos Alonso-Moreno
Pharmaceutics 2021, 13(10), 1705; https://doi.org/10.3390/pharmaceutics13101705
Received: 15 September 2021 / Revised: 8 October 2021 / Accepted: 12 October 2021 / Published: 15 October 2021
(This article belongs to the Special Issue Targeted Nanotherapy in Cancer Disease)
In the last decade, antibody-drug conjugates (ADCs), normally formed by a humanized antibody and a small drug via a chemical cleavable or non-cleavable linker, have emerged as a potential treatment strategy in cancer disease. They allow to get a selective delivery of the chemotherapeutic agents at the tumor level, and, consequently, to improve the antitumor efficacy and, especially to decrease chemotherapy-related toxicity. Currently, nine antibody-drug conjugate-based formulations have been already approved and more than 80 are under clinical trials for the treatment of several tumors, especially breast cancer, lymphomas, and multiple myeloma. To date, no ADCs have been approved for the treatment of gynecological formulations, but many formulations have been developed and have reached the clinical stage, especially for the treatment of ovarian cancer, an aggressive disease with a low five-year survival rate. This manuscript analyzes the ADCs formulations that are under clinical research in the treatment of gynecological carcinomas, specifically ovarian, endometrial, and cervical tumors. View Full-Text
Keywords: auristatins; cervical cancer; endometrial cancer; maytansinoids; mirvetuximab soravtansine; ovarian cancer; sacituzumab govitecan; targeted-chemotherapy; trastuzumab deruxtecan auristatins; cervical cancer; endometrial cancer; maytansinoids; mirvetuximab soravtansine; ovarian cancer; sacituzumab govitecan; targeted-chemotherapy; trastuzumab deruxtecan
Show Figures

Figure 1

MDPI and ACS Style

Martín-Sabroso, C.; Lozza, I.; Torres-Suárez, A.I.; Fraguas-Sánchez, A.I. Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives. Pharmaceutics 2021, 13, 1705. https://doi.org/10.3390/pharmaceutics13101705

AMA Style

Martín-Sabroso C, Lozza I, Torres-Suárez AI, Fraguas-Sánchez AI. Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives. Pharmaceutics. 2021; 13(10):1705. https://doi.org/10.3390/pharmaceutics13101705

Chicago/Turabian Style

Martín-Sabroso, Cristina, Irene Lozza, Ana I. Torres-Suárez, and Ana I. Fraguas-Sánchez 2021. "Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives" Pharmaceutics 13, no. 10: 1705. https://doi.org/10.3390/pharmaceutics13101705

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop